Weight Management Injections

Prescribing Mounjaro® (tirzepatide) in Primary Care – SE London ICB update

Key messages (with further detail below)

· As agreed by NHS England (NHSE), 23 June 2025 will see the beginning of access to the drug Mounjaro® (tirzepatide) for the management of obesity in primary care settings to a small group of specific eligible patients.

· Mounjaro® (tirzepatide) will not be accessible to everyone who wishes to use it. People with the highest health risks and who meet the specified NHSE clinical criteria will be prioritised as part of the national phased roll out plan.

· SE London ICB is still working on making a Primary Care pathway available for the relatively small number of people in SE London (about 2000) who meet the qualifying criteria.

· To ensure consistency, clinical oversight, and system-wide coordination, this Year 1 pilot will be a centrally commissioned ICB pathway. This will not be operational by 23 June, however we anticipate it will go live before the end of July.

In the interim eligible patients can continue to access weight management medication through specialist weight management services (SWMS).

· Practices should not seek to establish their own local services in Year 1 or prescribe Mounjaro® (tirzepatide) for weight loss in isolation of SWMS or the commissioned primary care pathway, and there is no funding to support individual GP practices to do this.

Following on from our previous communication describing the agreed Interim Policy

For more information please visit NHS England » Weight management injections